Lupin Pharmaceuticals announced that the FDA has approved Suprax (cefixime) 400mg capsules.

Suprax is a 3rd generation cephalosporin antibiotic indicated in treatment of susceptible infections, including pharyngitis, tonsillitis, acute bronchitis, acute exacerbation of chronic bronchitis, uncomplicated UTIs and cervical or urethral gonorrhea. The 3rd generation cephalosporins exhibit enhanced activity against gram-negative bacilli that are resistant to other β-lactams.

Suprax is already available as 400mg strength tablets and 100mg/5mL and 200mg/5mL strength oral suspensions. Lupin expects to commence shipping Suprax capsules in the near future.

For more information call (866) 587-4617 or visit